BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European ...
BiomX to present positive Phase 1b/2a data for BX004 at ERS Congress 2024, showing favorable safety and efficacy in CF patients with chronic Pseudomonas aeruginosa pulmonary infections.
Reference News
BiomX Inc. to present Phase 1b/2a study data of BX004, a phage therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections, at the European Respiratory Society Congress in Vienna. BX004 demonstrated safety and efficacy, including in patients on standard care treatment, with plans for a Phase 2b trial.
BiomX to present Phase 1b/2a BX004 study data at NACFC in Boston, showing efficacy in reducing Pseudomonas aeruginosa in CF patients, with plans for a Phase 2b trial.
BiomX to present positive Phase 1b/2a data for BX004 at ERS Congress 2024, showing favorable safety and efficacy in CF patients with chronic Pseudomonas aeruginosa pulmonary infections.